Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Neuroscience. 2019 Nov 26;425:280–300. doi: 10.1016/j.neuroscience.2019.11.020

Figure 2. MDZ + 10 mg/kg ganaxolone demonstrates anticonvulsant, but not neuroprotective, activity in both the soman (A) and DFP (B) models of SE.

Figure 2.

Ai) Change in gamma power relative to baseline in soman-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=9) or MDZ + 50% HPBCD in water (blue, n=9). Aii) Change in mean spike rate frequency relative to baseline in soman-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=9) or MDZ + 50% HPBCD in water (blue, n=9). Aiii) Fluoro-Jade B staining in vulnerable brain regions in soman-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=7) or MDZ + 50% HPBCD in water (blue, n=11). Bi) Change in gamma power relative to baseline in DFP-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=19) or MDZ + 50% HPBCD in water (blue, n=20). Bii) Change in mean spike rate frequency relative to baseline in DFP-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=19) or MDZ + 50% HPBCD in water (blue, n=20). Biii) Fluoro-Jade B staining in vulnerable brain regions in DFP-exposed rats that received MDZ + 10 mg/kg ganaxolone (red, n=18) or MDZ + 50% HPBCD in water (blue, n=20). Data represents mean ± SEM. Statistical significance: *p<0.05, **p<0.01